N/A
N=2
Feasibility Study: Heavy Water Tissue Labeling Protocol
Skin Laxity
Bottom Line
View on ClinicalTrials.gov: NCT01708525 ↗Enrolled (actual)
2
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcome: Primary: Rate of Collagen Synthesis — 15.71; 21.22; 36.11; 51.80 percentage of new collagen synthesized
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ulthera® System Treatment (Device); Heavy Water (Other)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Ulthera, Inc
- Primary completion
- Nov 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Collagen Synthesis |
15.71; 21.22; 36.11; 51.80; 18.53; 29.69 | — |
Summary
Enrolled subjects undergo tissue labeling to evaluate the rate of collagen synthesis in tissue treated with the Ulthera® System compared to control tissue.
Eligibility Criteria
Inclusion Criteria
- Male or female, age 30 to 65 years scheduled for rhytidectomy.
- Subject in good health.
- Understands and accepts the obligation not to undergo any other procedures in the areas to be treated.
- Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
- Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at Visit 1 and be willing and able to use an acceptable method of birth control.
- Absence of physical or psychological conditions unacceptable to the investigator.
- Willingness and ability to provide written consent for study-required photography and adherence to photography procedures (i.e., removal of jewelry and makeup).
- Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.
Exclusion Criteria
- Presence of an active systemic or local skin disease that may affect wound healing.
- Severe solar elastosis.
- Significant scarring in areas to be treated.
- Open wounds or lesions in the area to be treated.
- Severe or cystic acne on the area to be treated.
- Presence of a metal stent or implant in the facial area to be treated.
- Inability to understand the protocol or to give informed consent.
- Microdermabrasion, or prescription level glycolic acid treatments to the submental area within two weeks prior to study participation or during the study.
- Excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area to be treated.
- BMI equal to or greater than 30.
Data sourced from ClinicalTrials.gov (NCT01708525). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.